Table 4. 1.
INSS stage | Age | MYCN status | Histology | Risk group | 3-year survival rate |
---|---|---|---|---|---|
1 | 0–21 years | Any | Any | Low | >90% |
2 | 0–21 years | Non-Amp | Any | Low | 70–90% in this stage |
1–21 years | Amp | Favorable | Low | ||
1–21 years | Amp | Unfavorable | High | ||
3 | <1 year | Non-Amp | Any | Intermediate | 30–50% in this stage |
1–21 years | Non-Amp | Favorable | Intermediate | ||
0–21 years | Amp | Any | High | ||
0–21 years | Non-Amp | Unfavorable | High | ||
4 | <1 year | Non-Amp | Any | Intermediate | <30% in this stage |
0–21 years | Amp | Any | High | ||
4S | <1 year | Non-Amp | Favorable | Low | 50–80% in this stage |
<1 year | Non-Amp | Unfavorable | Intermediate | ||
<1 year | Amp | Any | High |
INSS, International Neuroblastoma Staging System; Amp, amplified; Non-Amp, not amplified.